Wave Life Sciences Ltd. (WVE)

Market Cap	2.49B
Revenue (ttm)	109.23M +103.7%
Net Income	-121.95M
EPS	-0.74
Shares Out	183.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,190
Open	13.31
Previous Close	13.25
Day's Range	13.30 - 13.77
52-Week Range	5.28 - 21.73
Beta	-1.82
Analysts	Strong Buy
Price Target	29.94 (+119.66%)
Earnings Date	Mar 3, 2026

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 288
• Stock Exchange: NASDAQ
• Ticker Symbol: WVE
• Website: https://wavelifesciences.com

Financial Performance

In 2024, Wave Life Sciences's revenue was $108.30 million, a decrease of -4.42% compared to the previous year's $113.31 million. Losses were -$97.01 million, 68.7% more than in 2023.

Analyst Summary

According to 16 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $29.94, which is an increase of 119.66% from the latest price.

Price Target

$29.94

(119.66% upside)

Analyst Consensus: Strong Buy